Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $42.07 USD
Change Today +0.10 / 0.24%
Volume 66.7K
FMS On Other Exchanges
New York
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius medical care-adr (FMS) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/27/15 - $43.93
52 Week Low
05/20/14 - $31.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

fresenius medical care-adr (FMS) Related Businessweek News

No Related Businessweek News Found

fresenius medical care-adr (FMS) Details

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care services related to the dialysis treatment a patient receives with end stage renal disease (ESRD); and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of 3,361 outpatient dialysis clinics in approximately 45 countries worldwide; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. The company also provides pharmacy services, such as delivery and supply of renal medications to patients at homes or to dialysis clinics directly; vascular, cardiovascular, and endovascular specialty services; and offers products for the treatment of ESRD. In addition, it offers laboratory services that include blood, urine, and other bodily fluid testing services; and hemodialysis (HD) machines, modular components for dialysis machines, polysulfone dialyzers, bloodlines, HD solutions and concentrates, needles, connectors, machines for water treatment, data administration systems, dialysis chairs, phosphate binders, iron products, and other renal drug products. Further, the company provides peritoneal dialysis systems and solutions for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis; and adsorbers, which are filters used in other extracorporeal therapies; and distributes specific instruments for vascular access, as well as other supplies, such as bandages, clamps, and injections. The company sells its products to clinics, hospitals, and specialized treatment clinics through local sales forces, independent distributors, dealers, and sales agents. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.

101,543 Employees
Last Reported Date: 04/30/15
Founded in 1996

fresenius medical care-adr (FMS) Top Compensated Officers

Chairman of the Management Board for Freseniu...
Total Annual Compensation: $2.2M
Chief Financial Officer of Fresenius Medical ...
Total Annual Compensation: $1.3M
Chief Executive Officer of Fresenius Medical ...
Total Annual Compensation: $1.5M
Chief Executive Officer of Asia Pacific Divis...
Total Annual Compensation: $1.2M
Chief Executive Officer of Global Manufacturi...
Total Annual Compensation: $931.0K
Compensation as of Fiscal Year 2014.

fresenius medical care-adr (FMS) Key Developments

Fresenius Medical Care AG & Co. KGAA Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015

Fresenius Medical Care AG & Co. KGAA reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total net revenues were $3,959,927,000 against $3,563,592,000 a year ago. Operating income was $504,400,000 against $444,895,000 a year ago. Income before income taxes was $402,292,000 against $348,634,000 a year ago. Net income attributable to shareholders of FMC-AG&Co. KGaA was $209,548,000 or $0.69 fully diluted earnings per share against $205,462,000 or $0.68 fully diluted earnings per share a year ago. Net cash provided by operating activities was $447,270,000 against $112,294,000 a year ago. Purchases of property, plant and equipment was $201,196,000 against $199,631,000 a year ago. Acquisitions and investments, net of cash acquired, and purchases of intangible assets were $21,896,000 against $137,157,000 a year ago. Total EBITDA was $680 million against $612 million a year ago. Cash provided by operating activities is impacted by the profitability of its business, the development of its working capital, principally inventories, receivables. The increase in 2015 versus 2014 was mainly a result of the $115 million payment for the W.R. Grace bankruptcy settlement which occurred in the first quarter of 2014, the impact of other working capital items such as the timing related to the payment of payables and other liabilities as well as decreased inventory.

Fresenius Medical Care Seeks Acquisitions

Fresenius Medical Care AG & Co. KGAA (DB:FME) is looking for acquisitions. Fresenius Medical Care expects to spend around $1 billion on capital expenditures and around $400 million on acquisitions in 2015.

Sequana Medical Signs Collaboration Agreement with Fresenius Medical Care for the Marketing and Distribution of the alfapump System

Sequana Medical announced that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system. The alfapump system is an automated, fully implantable pump system for the management of ascites. Ascites is a frequent complication of late-stage liver disease and certain cancers, and affects hundreds of thousands of patients across the world. Under the terms of the agreement, Fresenius Medical Care has the rights to distribute the alfapump system across Europe, Middle East and Africa markets not currently serviced by Sequana Medical’s own distribution channels. The first countries to go live are Austria, Belgium, the Netherlands and Poland. Fresenius Medical Care will also engage in collaborative market development and reimbursement programs in these markets. The alfapump system is the first real alternative to large-volume paracentesis, a lengthy, invasive and painful procedure which can require weekly hospital visits for drainage of excess fluid. By moving ascites to the bladder as it forms, the alfapump system prevents the build-up of fluid and its complications, improving patient quality of life and reducing hospital visits. Sequana Medical has recently launched its next generation product, alfapump with DirectLink Technology, which allows clinicians to monitor the alfapump remotely. The company also began an FDA trial of the alfapump system earlier this month.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FMS:US $42.07 USD +0.10

FMS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.43 USD +0.69
Becton Dickinson and Co $142.19 USD +1.32
DaVita HealthCare Partners Inc $82.40 USD +1.30
Mylan NV $73.89 USD +1.63
Toray Industries Inc ¥1,034 JPY -8.00
View Industry Companies

Industry Analysis


Industry Average

Valuation FMS Industry Range
Price/Earnings 24.3x
Price/Sales 1.5x
Price/Book 2.5x
Price/Cash Flow 25.0x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS MEDICAL CARE-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at